Science Driven CRO

Science Driven CRO


Clinical Development in Challenging Cancers (03): Ovarian Clear Cell Carcinoma (OCCC)

Click to read online

In the third article in the series. Our Medics take a closer look at treatment, therapeutic challenges and Clinical Development in Ovarian Clear Cell Carcinoma (OCCC):

“Ovarian clear cell carcinoma (OCCC) is a rare histological subtype of epithelial ovarian cancers (EOCs), with an incidence, among EOCs, of 4-12% in Western countries [1–3] and a higher ratio of over 20% in Japan [4,5]. Histologically, EOCs are classified into serous, mucinous, endometroid, clear cell and undifferentiated subtypes. Ovarian cancer is already the leading cause of death among gynecological malignancies in the US [6], in addition, the OCCC subtype presents a lower response rate to traditional platinum-based chemotherapy and is generally associated with poorer prognosis across all stages compared to other EOC subtypes [2,4,7–9…]”

We invite you to read the entire article (pages 42-47) by clicking the cover image.